OmniAb Inc SEC Filings

OmniAb, Inc. President and CEO Matthew W. Foehr reported routine equity compensation activity. On April 7, 2026, 36,459 Restricted Stock Units vested and were converted into the same number of OmniAb common shares at no exercise price. To satisfy tax withholding obligations tied to this vesting, 19,244 shares of common stock were sold in mandated “sell-to-cover” transactions at a weighted average price of $1.49 per share, rather than at Foehr’s discretion. Following these transactions, Foehr directly holds 4,420,492 shares of OmniAb common stock and 309,376 RSUs, indicating that the sale represents a small portion of his overall equity position.

Morgan Stanley Smith Barney LLC submitted a Form 144 notice for proposed sale of 36,459 shares of restricted common stock on 04/07/2026, listed as compensation securities. The filing also records prior sales of 20,754 shares on 02/17/2026 and 30,843 shares on 02/18/2026.

OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no cost. To cover tax withholding on this vesting, 6,913 common shares were sold in a mandated sell-to-cover transaction at a weighted average price of $1.49 per share, rather than as a discretionary sale. After these events, he directly holds 261,483 shares of OmniAb common stock, reflecting prior transfers including 13,997 shares delivered to an ex-spouse under a domestic relations order.

OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported routine equity compensation activity. On April 7, 2026, 13,542 Restricted Stock Units vested, converting into the same number of common shares at no exercise price. To satisfy tax withholding obligations under OmniAb’s equity incentive plans, 7,157 common shares were sold in a mandated “sell-to-cover” transaction at a weighted-average price of $1.49 per share, rather than as a discretionary trade. Following these transactions, Berkman directly holds 399,085 shares of OmniAb common stock and 111,042 RSUs, indicating that only a small portion of his position was sold.

OABI filed a Rule 144 notice to sell 13,542 shares of common stock. The filing lists these as restricted stock issued for compensation with an intended sale date of 04/07/2026. The notice also reports prior sales of 6,990 shares on 02/17/2026 and 9,673 shares on 02/18/2026.

OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.

OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.

OmniAb, Inc. reported weaker 2025 results but outlined growth plans and tighter cost control. Full-year 2025 revenue was $18.7 million, down from $26.4 million in 2024, mainly due to lower license, milestone and service revenue, partly offset by new xPloration and higher royalty revenue. The company posted a 2025 net loss of $64.8 million, or $0.57 per share, slightly higher than the prior year’s $62.0 million loss.

Research and development expense fell to $47.8 million and general and administrative expense to $29.2 million, helped by lower headcount, share-based compensation and legacy ion channel spending, though results included a $3.9 million impairment. OmniAb ended 2025 with $54.0 million in cash, cash equivalents and short-term investments.

For 2026, OmniAb guides to $25–$30 million in revenue and $80–$85 million in GAAP costs and operating expenses, with non‑GAAP cash costs of $50–$55 million, and expects year-end cash of $30–$35 million and an effective tax rate of approximately 0%. The company highlights 107 active partners, 407 active programs, the launch of its OmniUltra transgenic chicken platform, and multiple partner programs progressing through clinical development.

OmniAb, Inc. Chief Legal Officer Charles S. Berkman reported multiple equity compensation moves and a small mandated share sale. He acquired 18,750 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs), and was granted 60,000 new RSUs and 600,000 stock options, all held directly.

To cover tax withholding on the RSU vesting, 9,673 common shares were sold in a required "sell-to-cover" transaction at a weighted average price of $1.71, with individual trades between $1.68 and $1.73. After these transactions, he directly owned 392,700 shares of common stock, 124,584 RSUs and 600,000 stock options.

OmniAb, Inc. Executive VP, Finance and CFO Kurt A. Gustafson reported multiple equity transactions. He acquired 18,750 shares of common stock through the vesting and conversion of restricted stock units and received new awards of 60,000 RSUs and stock options for 600,000 shares.

Following these awards, he sold 9,301 shares of common stock at a weighted average price of $1.71 per share to cover tax withholding obligations under a mandatory sell-to-cover arrangement, which the company’s equity plans require rather than a discretionary trade.